<- Home

Compare Records

A side-by-side evidence inventory. Comparison means coverage, grade mix, domains, and source context, not a recommendation.

Each cell shows the strongest-graded finding in that domain, with how many findings it stands for. A single cell does not mean a single study. Open either drug for the full list. This is a navigation aid, not a ranking or a treatment comparison.

Tirzepatide

MARKETED

Semaglutide

MARKETED

safety-other

Tirzepatide — strongest of 13 High evidence Tirzepatide is contraindicated in the US for personal/family history of MTC or MEN 2 (also a boxed warning) and serious... Mounjaro (tirzepatide) US Prescribing Information, Eli Lilly; FDA/MHRA/TGA advisories

Semaglutide — strongest of 21 High evidence NET VERDICT (early-worsening diabetic retinopathy): SUSTAIN-6 found retinopathy complications significantly MORE frequent with... Marso SP et al. (SUSTAIN-6), NEJM, 2016

Specific groups of people

Tirzepatide — strongest of 10 High evidence The EU SmPC states tirzepatide could be considered for use during breast-feeding. Mounjaro (tirzepatide) EU Summary of Product Characteristics (EMA)

Semaglutide — strongest of 11 High evidence The EU SmPC states semaglutide should not be used during breast-feeding. Ozempic (semaglutide) EU Summary of Product Characteristics (EMA)

Head-to-head comparisons

Tirzepatide — strongest of 7 High evidence DIRECT head-to-head CVOT (SURPASS-CVOT, T2D + ASCVD). Tirzepatide (up to 15 mg) was NON-INFERIOR to dulaglutide 1.5 mg for... Nicholls SJ et al. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 ...

Semaglutide — strongest of 1 Moderate evidence DIRECT head-to-head (SUSTAIN 7, T2D). Semaglutide was superior to dulaglutide at matched low and high doses for both HbA1c and... Pratley RE, Aroda VR, Lingvay I, et al. Lancet Diabetes Endocrinol 2018 (SUSTAIN 7)

pharmacology

Tirzepatide — strongest of 18 High evidence Tirzepatide is injected subcutaneously once weekly into the abdomen, thigh or upper arm with site rotation, at any time of day... Mounjaro (tirzepatide) US Prescribing Information, Eli Lilly; FDA/MHRA/TGA advisories

Semaglutide — strongest of 20 High evidence For Ozempic, a missed dose should be administered as soon as possible within 5 days after the missed dose; if more than 5 days... Ozempic (semaglutide) US Prescribing Information, Novo Nordisk

Heart and circulation

Tirzepatide — strongest of 2 High evidence In T2D with established ASCVD, tirzepatide was NON-INFERIOR to dulaglutide for 3-point MACE but did NOT meet superiority. The... Nicholls SJ et al. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 ...

Semaglutide — strongest of 9 High evidence In adults aged >=45 with pre-existing CVD and overweight/obesity (BMI >=27) but WITHOUT diabetes, once-weekly s.c. semaglutide... Lincoff AM et al. (SELECT), NEJM, 2023

blood-pressure

Tirzepatide — strongest of 1 High evidence Tirzepatide reduced 24-hour ambulatory systolic BP versus placebo (SURMOUNT-1 ABPM substudy); effect partly weight-mediated. de Lemos JA et al. (SURMOUNT-1 ABPM), Hypertension, 2024;81(4):e41-e43

Semaglutide — strongest of 1 Low evidence Once-weekly semaglutide 2.4 mg reduced office SBP/DBP versus placebo across the STEP 1-5 programme. Amaro A et al. (STEP cardiometabolic review), Postgrad Med, 2022;134(sup1):18-27

Heart failure

Tirzepatide — strongest of 2 High evidence SUMMIT: in HFpEF with obesity, tirzepatide reduced the composite of CV death or worsening HF event and improved KCCQ-CSS versus... Packer M et al. (SUMMIT), NEJM, 2025;392:427-437

Semaglutide — strongest of 5 High evidence STEP-HFpEF: in HFpEF with obesity but without diabetes, semaglutide improved HF symptoms/physical limitations (KCCQ-CSS) versus... Kosiborod MN et al. (STEP-HFpEF), NEJM, 2023;389:1069-1084

Heart rate

Tirzepatide — strongest of 1 High evidence Tirzepatide raises heart rate modestly and dose-dependently versus placebo. de Lemos JA et al. (SURMOUNT-1 ABPM), Hypertension, 2024;81(4):e41-e43

Semaglutide — strongest of 1 Low evidence Semaglutide produces a modest resting heart-rate rise versus placebo (class chronotropic effect). Marso SP et al. (SUSTAIN-6), NEJM, 2016;375:1834-1844; plus class HR summaries